Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); XT-8 Placements Lead Again
Tweet
Share
E-mailGet Alerts GNMK Hot Sheet
Price: $24.04 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK), PT $11.
Canaccord analyst says, "GNMK announced what we view as solid Q1/11 results. EPS were $(0.56) versus our forecast of $(0.55), and revenues were $0.8M versus our estimate of $0.7M."
"2011 outlook positive. We expect GNMK to place between 55-65 XT-8 instruments in 2011, for a cumulative installed base of 130-140 along with two new test launches (Respiratory Virus Panel and HCV research use only) this year."
For more ratings news on GenMark Diagnostics click here and for the rating history of GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $5.87 yesterday.
Canaccord analyst says, "GNMK announced what we view as solid Q1/11 results. EPS were $(0.56) versus our forecast of $(0.55), and revenues were $0.8M versus our estimate of $0.7M."
"2011 outlook positive. We expect GNMK to place between 55-65 XT-8 instruments in 2011, for a cumulative installed base of 130-140 along with two new test launches (Respiratory Virus Panel and HCV research use only) this year."
For more ratings news on GenMark Diagnostics click here and for the rating history of GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $5.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
